Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Intellia Thera CS (NTLA)

Intellia Thera CS (NTLA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,093,435
  • Shares Outstanding, K 115,830
  • Annual Sales, $ 57,880 K
  • Annual Income, $ -519,020 K
  • EBIT $ -479 M
  • EBITDA $ -468 M
  • 60-Month Beta 2.13
  • Price/Sales 19.19
  • Price/Cash Flow N/A
  • Price/Book 1.38

Options Overview Details

View History
  • Implied Volatility 86.62% (-6.92%)
  • Historical Volatility 59.51%
  • IV Percentile 51%
  • IV Rank 22.59%
  • IV High 154.61% on 10/27/25
  • IV Low 66.78% on 01/21/25
  • Expected Move (DTE 17) 1.18 (12.93%)
  • Put/Call Vol Ratio 0.94
  • Today's Volume 1,216
  • Volume Avg (30-Day) 2,228
  • Put/Call OI Ratio 0.36
  • Today's Open Interest 115,629
  • Open Int (30-Day) 120,869
  • Expected Range 7.96 to 10.32

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 26 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.99
  • Number of Estimates 10
  • High Estimate -0.89
  • Low Estimate -1.10
  • Prior Year -1.24
  • Growth Rate Est. (year over year) +20.16%

Price Performance

See More
Period Period Low Period High Performance
1-Month
8.09 +13.05%
on 12/02/25
9.95 -8.14%
on 12/08/25
+0.15 (+1.67%)
since 11/28/25
3-Month
7.95 +14.97%
on 11/21/25
28.25 -67.65%
on 10/20/25
-7.78 (-45.98%)
since 09/29/25
52-Week
5.90 +54.92%
on 04/07/25
28.25 -67.65%
on 10/20/25
-2.83 (-23.64%)
since 12/27/24

Most Recent Stories

More News
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., Dec. 05, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies,...

NTLA : 9.14 (-3.18%)
Longevity-Focused Health Fueling U.S. Anti-Aging Products Market Projected to Reach $27 Billion By 2033

EQNX::TICKER_START (OTCQB:AVAI),(NASDAQ:RXRX),(NASDAQ:NTLA),(NASDAQ:ZYME),(NYSE:ANVS) EQNX::TICKER_END

AVAI : 0.2910 (-0.51%)
ANVS : 3.50 (-2.78%)
RXRX : 4.13 (-2.82%)
ZYME : 26.74 (-0.48%)
NTLA : 9.14 (-3.18%)
Longevity-Focused Health Fueling U.S. Anti-Aging Products Market Projected to Reach $27 Billion By 2033

MarketNewsUpdates News Commentary NEW YORK, Nov. 18, 2025 (GLOBE NEWSWIRE) -- The advance anti-aging therapies market is expanding quickly fueled by a larger senior population and increased...

AVAI : 0.2910 (-0.51%)
ANVS : 3.50 (-2.78%)
RXRX : 4.13 (-2.82%)
ZYME : 26.74 (-0.48%)
NTLA : 9.14 (-3.18%)
Should You Buy the Dip in Intellia Therapeutics Stock?

A patient’s death shook Intellia Therapeutics and sank its stock. Should investors buy the dip or steer clear?

SRPT : 21.82 (-1.36%)
REGN : 780.50 (-0.57%)
PFE : 25.00 (-0.36%)
NTLA : 9.14 (-3.18%)
Is This Beaten-Down Cathie Wood Stock Still a Buy?

Intellia’s shares plunged 23% after its Q3 results showed a pipeline setback. Nonetheless, Cathie Wood’s stake in the company is expanding.

NTLA : 9.14 (-3.18%)
ARKK : 78.61 (-1.37%)
Intellia Therapeutics Presents Positive Longer-Term Phase 1 Data of Nexiguran Ziclumeran (nex-z) in Patients with Transthyretin (ATTR) Amyloidosis with Cardiomyopathy

One-time treatment of nex-z led to consistently rapid, deep and durable reduction in serum TTR through three years of follow-up Consistent trend in disease stability or improvement in multiple measures...

NTLA : 9.14 (-3.18%)
Intellia Therapeutics Presents Positive Pooled Phase 1/2 Data of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema

Deep, stable and durable reductions in kallikrein observed  Among 32 patients who received a 50 mg dose of lonvo-z as of data cutoff: 31 (97%) were attack-free and long-term prophylaxis (LTP)-free...

NTLA : 9.14 (-3.18%)
Stocks Recover on Government Reopening Hopes

The S&P 500 Index ($SPX ) (SPY ) on Friday closed up +0.13%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed up +0.16%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -0.28%. December E-mini...

SOLV : 80.09 (-0.46%)
AMAT : 263.05 (+0.44%)
ADI : 275.63 (-0.44%)
EXPE : 286.82 (-0.26%)
AKAM : 88.24 (-0.20%)
$IUXX : 25,525.56 (unch)
ZNH26 : 112-215 (-0.04%)
ESH26 : 6,952.00 (-0.04%)
QCOM : 173.43 (-0.79%)
AMD : 215.61 (+0.29%)
LRCX : 175.87 (-1.24%)
OLED : 119.24 (-0.30%)
Economic Angst Weighs on Stocks

The S&P 500 Index ($SPX ) (SPY ) today is down -0.95%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -0.54%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -1.55%. December E-mini S&P futures...

SOLV : 80.09 (-0.46%)
AMAT : 263.05 (+0.44%)
GOOGL : 313.56 (+0.02%)
AAPL : 273.76 (+0.13%)
EXPE : 286.82 (-0.26%)
AKAM : 88.24 (-0.20%)
$IUXX : 25,525.56 (unch)
ZNH26 : 112-215 (-0.04%)
MSFT : 487.10 (-0.13%)
TSLA : 459.64 (-3.27%)
ESH26 : 6,952.00 (-0.04%)
GFS : 35.85 (+0.11%)
Stocks Decline on Weakness in Megacap Tech Stocks and Chipmakers

The S&P 500 Index ($SPX ) (SPY ) today is down -0.79%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -0.46%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -1.13%. December E-mini S&P futures...

SOLV : 80.09 (-0.46%)
AMAT : 263.05 (+0.44%)
GOOGL : 313.56 (+0.02%)
AAPL : 273.76 (+0.13%)
EXPE : 286.82 (-0.26%)
AKAM : 88.24 (-0.20%)
$IUXX : 25,525.56 (unch)
FLR : 40.40 (-1.03%)
ZNH26 : 112-215 (-0.04%)
MSFT : 487.10 (-0.13%)
TSLA : 459.64 (-3.27%)
ESH26 : 6,952.00 (-0.04%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Strengthening short term outlook on maintaining the current direction.

See More Share

Business Summary

Intellia Therapeutics is a leading clinical-stage genome editing company focused on developing CRISPR/Cas9-based therapeutics. The company is pursuing two primary approaches to fully realize the transformative potential of CRISPR/Cas9 in vivo programs that use intravenously administered CRISPR as the...

See More

Key Turning Points

3rd Resistance Point 9.72
2nd Resistance Point 9.54
1st Resistance Point 9.34
Last Price 9.14
1st Support Level 8.96
2nd Support Level 8.78
3rd Support Level 8.58

See More

52-Week High 28.25
Fibonacci 61.8% 19.71
Fibonacci 50% 17.08
Fibonacci 38.2% 14.44
Last Price 9.14
52-Week Low 5.90

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar